436 related articles for article (PubMed ID: 18259162)
1. 2007--a banner year for biotech.
Lawrence S
Nat Biotechnol; 2008 Feb; 26(2):150. PubMed ID: 18259162
[No Abstract] [Full Text] [Related]
2. 2005: biotech partners up.
Lawrence S
Nat Biotechnol; 2006 Feb; 24(2):126. PubMed ID: 16465145
[No Abstract] [Full Text] [Related]
3. Biotech financing retrenches in Q2.
Lawrence S
Nat Biotechnol; 2006 Aug; 24(8):883. PubMed ID: 16900116
[No Abstract] [Full Text] [Related]
4. Could bank loans solve Europe's biotech financing slump?
Mitchell P
Nat Biotechnol; 2005 Dec; 23(12):1459-60. PubMed ID: 16333276
[No Abstract] [Full Text] [Related]
5. Upward trend in financing continues, but fewer feel flush.
Lawrence S
Nat Biotechnol; 2007 Jan; 25(1):3. PubMed ID: 17211374
[No Abstract] [Full Text] [Related]
6. 2006: a stellar year for financing.
Lawrence S
Nat Biotechnol; 2007 Feb; 25(2):156. PubMed ID: 17287738
[No Abstract] [Full Text] [Related]
7. State of biotech sector--2005.
Lawrence S
Nat Biotechnol; 2006 Jun; 24(6):603. PubMed ID: 16763577
[No Abstract] [Full Text] [Related]
8. 1Q13--Stocks reach all-time high.
Yang W
Nat Biotechnol; 2013 May; 31(5):378. PubMed ID: 23657383
[No Abstract] [Full Text] [Related]
9. Biotech on pace for record year.
Yang W
Nat Biotechnol; 2011 Sep; 29(9):780. PubMed ID: 21904312
[No Abstract] [Full Text] [Related]
10. Private biotech 2004--the numbers.
Hodgson J
Nat Biotechnol; 2006 Jun; 24(6):635-41. PubMed ID: 16763589
[TBL] [Abstract][Full Text] [Related]
11. Public biotechnology 2005--the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2006 Jun; 24(6):625-34. PubMed ID: 16763588
[TBL] [Abstract][Full Text] [Related]
12. The rise of European venture capital for biotechnology.
Howell M; Trull M; Dibner MD
Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
[No Abstract] [Full Text] [Related]
13. VC funding hits high in Q1.
Lawrence S
Nat Biotechnol; 2007 May; 25(5):496. PubMed ID: 17483825
[No Abstract] [Full Text] [Related]
14. Does biotech M&A benefit investors?
Jacobs T
Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
[No Abstract] [Full Text] [Related]
15. White biotechnology: ready to partner and invest in.
Kircher M
Biotechnol J; 2006; 1(7-8):787-94. PubMed ID: 16897821
[TBL] [Abstract][Full Text] [Related]
16. Lack of private financing hobbles emerging biotech regions.
Jia H; Jayarama KS; Astvatsaturyan M
Nat Biotechnol; 2006 Jan; 24(1):7-9. PubMed ID: 16404378
[No Abstract] [Full Text] [Related]
17. Korean biotechs seize opportunity to list on public markets.
Louët S
Nat Biotechnol; 2005 Oct; 23(10):1189-90. PubMed ID: 16211042
[No Abstract] [Full Text] [Related]
18. Public markets show signs of life.
Mitchell P
Nat Biotechnol; 2003 Aug; 21(8):833-4. PubMed ID: 12894181
[No Abstract] [Full Text] [Related]
19. Public biotech 2006 - the numbers.
Lähteenmäki R; Lawrence S
Nat Biotechnol; 2007 Jul; 25(7):729-37. PubMed ID: 17621294
[No Abstract] [Full Text] [Related]
20. Public biotech 2009-the numbers.
Huggett B; Hodgson J; Lähteenmäki R
Nat Biotechnol; 2010 Aug; 28(8):793-9. PubMed ID: 20697401
[No Abstract] [Full Text] [Related]
[Next] [New Search]
